San Diego, Ca (PRWEB) October 07, 2013
Resource4thePeople today announced its latest update for consumers interested in litigation alleging that women who used the popular contraceptive NuvaRing suffered serious blood-clotting problems.
The majority of federal cases involving such litigation have been consolidated before a U.S. District Court judge in Missouri in what has been called the IN RE: NuvaRing Products Liability Litigation.
Resource4thePeople is reporting that the latest figures* from this multidistrict litigation involving similar allegations of blood-clotting problems from the use of NuvaRing show that the number of lawsuits has climbed to 1,340 cases as of the latest reporting period ending Sept. 11, 2013.
The court docket in the litigation** shows that the judge overseeing the cases, U.S. District Court Judge Rodney W. Sippel, has scheduled the first bellwether trial from this litigation to be held Jan. 27, 2013.
"We are encouraged that the judge has scheduled the first trial in the case and that consumers who are alleging that they suffered serious, life-threatening blood-clotting problems from the use of NuvaRing contraceptives will have their day in court," said Resource4thePeople.
"As these cases proceed to trial consumers who may have suffered similar allegations should be aware that they may have their own legal options to seek compensation in such cases and that our lawyers will remain available to review such claims."
Resource4thePeople is announcing that it will continue its policy of offering free consultations to consumers who are inquiring about their eligibility to file claims or lawsuits over similar allegations.
"However, there is always the possibility of legal time limits being involved so our recommendation is to contact us as soon as possible in order to protect all legal options," said Resource4thePeople.
The latest figures document an increase of 61 cases since the last reporting period in August among the cases being overseen by Judge Sippel involving common allegations that are summed up on the court’s multidistrict litigation web site and include the following language:
“NuvaRing is a prescription contraceptive device used by women throughout the United States. The individual plaintiffs in this matter claim that use of NuvaRing caused them injuries. They have filed suit in several state and federal courts alleging that the manufacturer of NuvaRing failed to adequately warn of the risks associated with the use of the product, and/or that the NuvaRing product is otherwise defective and unreasonably dangerous.”**
As this litigation progresses, other NuvaRing lawsuits continue to be filed, including one by lawyers for a California woman who, according to the complaint*** she filed in U.S. District Court in New Jersey, attributes a serious blood-clotting problem to her use of the NuvaRing contraceptive.
"This lawsuit is among hundreds of others in which women claim that the NuvaRing vaginal ring contraceptive has caused them to suffer life-threatening blood-clotting problems," said Resource4thePeople.
The California woman's lawsuit also alleges that the manufacturers of the contraceptive were aware that the NuvaRing put women at greater risk of suffering blood clots but failed to adequately inform consumers and government regulators.
Another such case**** was recently filed by a Louisiana woman who claims she suffered a pulmonary embolism as a result of her use of the NuvaRing IUD. The case was filed in U.S. District Court New Jersey and names Organon, USA, Inc. and Merck & Co, Inc. as defendants.
In addition to seeking damages for her medical expenses and other costs, the woman is seeking other damages against the defendants over allegations that they were aware of dangerous side effects from the use of the NuvaRing IUD but were negligent in failing to warn consumers and health care professionals, according to the court file.
The defendants “falsely marketed NuvaRing as a safe and effective contraceptive without alerting women to the serious risk of developing blood clots, deep vein thrombosis and/or pulmonary embolism,” according to the woman’s allegations in the court file.
Resource4thePeople said the progress of this litigation does not bar other women from filing their own NuvaRing lawsuits alleging serious, life-threatening blood-clotting problems and consumers will continue to be updated about key developments in the lawsuits.
In addition to the federal consolidated lawsuits, over 200 such state court cases are under the supervision of a judge in New Jersey Superior Court, where another multidistrict litigation***** is underway.
Named as defendants in these litigations are Organon Pharmaceuticals USA Inc., Organon International Inc. and Schering-Plough Corp., who, according to the court file, allegedly falsely marketed and sold the NuvaRing as a safe, efficient alternative to birth control pills.
The NuvaRing was approved by the Food and Drug Administration in 2001 after being created by Organon as a flexible IUD, or ring, hence the name. The IUD releases a low dose of etonogestrel and estrogen over three weeks, providing women the flexibility of a monthly contraceptive.
On Oct. 27, 2011 the FDA released the findings of government research that put women who used the NuvaRing or other IUDs with a similar mixture of hormones at a 56 percent higher risk of suffering blood clotting that led to deep vein thrombosis and pulmonary embolisms than women on birth control pills.******
Resource4thePeople also notes that NuvaRing has now posted a warning about the increased risks of suffering blood clots on the company’s web site under the heading of “IMPORTANT SAFETY INFORMATION."*******
**In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, U.S. District Court, Eastern District of Missouri
***Case # 2:2013cv04195, United States District Court for the District of New Jersey
**** Case # 2:13-cv-2933, U.S. District Court for New Jersey
***** In Re NuvaRing Litigation, Docket No. BER-L-3081-09, Bergen County, New Jersey Superior Court
******http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf FDA Oct. 27, 2011